JP MORGAN/CALL/BOSTON SCIENTIFIC/80/0.1/20.06.25 | Delayed Börse Stuttgart 02:09:14 14/06/2024 pm IST | ||
| 1.12 EUR | -2.61% |
|
| Current month | +6.67% | ||
| 1 month | +17.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 1.12 | -2.61% |
| 13/24/13 | 1.15 | -1.71% |
| 12/24/12 | 1.17 | -2.50% |
| 11/24/11 | 1.2 | +2.56% |
| 10/24/10 | 1.17 | +7.34% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 02:09 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK2LLA |
| ISIN | DE000JK2LLA6 |
| Date issued | 29/02/2024 |
| Strike | 80 $ |
| Maturity | 20/06/2025 (369 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.2 € |
|---|---|
| Lowest since issue | 0.67 € |
| Spread | 0.06 € |
| Spread % | 4.96% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.76
USD
Average target price
82.26
USD
Spread / Average Target
+7.16%
- Stock Market
- Warrants
- Warrant
